ClinicalTrials.gg
RecruitingNCT03073278Updated Feb 6, 2026

Focal Radiotherapy for Previously Treated Prostate Cancer Patients

An interventional study of Stereotactic Body Radiotherapy in Locally Recurrent Prostate Cancer, sponsored by Royal North Shore Hospital. Recruiting at 1 site in Australia. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Royal North Shore Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2017; still recruiting 9 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 260 studies in Prostatic Neoplasms with a site in Australia — 70 open to participants now, 134 under way, 41 of them phase 3. Prostatic Neoplasms · Australia.

Planned enrollment
204th of 245
36 · median 232
Started
2017
with 12 others
No phase
19 of 260
4 open now
Primary completion
2027-03
later than 57 of 133 live
Registered
96th of 260
by date
Lead sponsor
9 of 260
Royal North Shore Hospital

Among the 260 studies in Prostatic Neoplasms with a site in Australia, this one is the 204th largest by planned enrollment of the 245 interventional ones that give a count, is one of 13 that started in 2017, is one of 19 with no phase, reaches primary completion later than 57 of the 133 other live ones, and was the 96th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

70 of the 260 studies in Prostatic Neoplasms with a site in Australia are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Prostatic Neoplasms with a site in Australia, or all of them as a file.
02

Study summary

To examine the feasibility, safety and toxicity of focal stereotactic radiation treatment (SBRT) for locally recurrent prostate cancer.

Read the detailed description

Participants must have biopsy proven locally recurrent prostate cancer. Biopsy will be performed by a Urologist. Participants will have PSMA-PET (prostate-specific membrane antigen and positron emission tomography) scan and MRI in Radiology and Nuclear Medicine by experienced Radiologists in the Royal North Shore Hospital. before starting stereotactic radiotherapy. Participants will require fiducial markers inserted in the prostate and may require hydrogel insertion depending on the location of the recurrence. If these are required, it will be done by experienced radiation oncologists. Fiducial markers insertion involves inserting three gold markers into the prostate. It will be used to locate the prostate accurately during radiation treatment. Hydrogel is a temporary gel being injected into the space between the prostate and rectum to reduce the dose of radiation received by the rectum to minimise side effects from the treatment, Focal Stereotactic Body treatment (SBRT) will be used in the study. There are three groups of participants. Each group will receive different level of radiation dose to test the safety of increasing radiation dose. Group 1 will receive 36 grays (radiation dose unit, Gy)) in 6 treatments. Group 2 will receive 38 grays in 6 treatments and Group 3 will receive 40 grays in 6 treatments. The incremental dose escalation will cease if any excess acute toxicity or late grade 3 toxicity. SBRT will be delivered two to three times per week, every second day. The number of treatments per week will depend on the day of the week participants start their treatment. Participants will be reviewed weekly or second weekly. Toxicity will be recorded. A Safety Committee will be formed containing multi-disciplinary team members. All serious adverse events will be reported to the Principal Investigator and Human Research Ethics Committee within 24 hours.

03

Conditions studied

  • Locally Recurrent Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men > 4yrs from external beam radiotherapy (EBRT) meeting the Phoenix definition of biochemical failure or men > 5yrs from EBRT if and/or adjuvant androgen deprivation therapy (ADT) also used
  • Recurrence localised to less than 1 lobe of prostate on both PMSA and multi-parametric MRI (less than equal to cT2a)
  • Recurrence must be proven, with positive biopsies limited to the PET and MRI suspicious region.
  • at least 10yrs from time of SBRT
  • PSA \< 10

Exclusion criteria

Exclusion Criteria:

  • Recurrence in immediate proximity to rectum (unless able to have hydrogel)
  • Grade 3 or more toxicity from previous EBRT
  • for fiducial insertion
  • GS 8,9 or 10 disease previously (relative - consider if decent disease free interval)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Other
    Group 1

    This group of 12 patients will be given 36Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.

    Radiation: Stereotactic Body Radiotherapy

  • Other
    Group 2

    This group (12 patients) will be given 38Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.

    Radiation: Stereotactic Body Radiotherapy

  • Other
    group 3

    This group (12 patients) will be given 40Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.

    Radiation: Stereotactic Body Radiotherapy

Interventions

  • RadiationStereotactic Body Radiotherapy

    Each group will have different dose of stereotactic body radiotherapy (SBRT). Depending on which group patients are in.

06

What researchers measure

Primary outcomes

  1. feasibility of SBRT dose escalation. This will be assessed by the number of participants with grade 3 acute toxicity according to CTCAE version 4.3

    acute toxicity will be assessed weekly during treatment period to check whether dose escalation can be achieved

    Time frame: at weekly review through completion of each radiothrapy dose level, approximately one year

  2. safety of SBRT dose escalation. This will be assessed by the number of participants with grade 3 acute toxicity according to CTCAE version 4.3

    outcome will be assessed by reviewing toxicity weekly during the treatment period and at the end of each dose escalation

    Time frame: at weekly review through completion of each radiothrapy dose level, approximately one year

  3. Toxicity. This will be assessed by the number of participants with grade 3 acute toxicity according to CTCAE version 4.3 and RTOG toxicity score.

    outcome will be assessed by reviewing toxicity weekly and at the end of each dose escalation

    Time frame: at weekly review through completion of each radiothrapy dose level, approximately one year

Secondary outcomes

  1. Tolerability of conservation dose escalation in this cohort of patients

    outcome will be assessed by reviewing toxicity weekly or secondly weekly and at the end of each dose escalation

    Time frame: After each group of patients have completed radiotherapy and at 12 and 24 months follow-up. Patients will have routine follow-up 6 monthly for 1 year and then yearly for 10 years post treatment. But study outcomes will only be collected for 2 years.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — aim to present data in conferences and publications

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2017 (actual). Primary completion is estimated for Mar 2027, 119 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 119 months is above that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2017
First posted
Mar 8, 2017
StartActual
Apr 24, 2017
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03073278
Lead sponsor
Royal North Shore Hospital
Collaborators
Northern Sydney and Central Coast Area Health Service
Responsible party
Sponsor
First posted
Mar 8, 2017
Start date
Apr 24, 2017
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Feb 6, 2026

Study contacts

Carolyn Kwong
Contact
carolyn.kwong@health.nsw.gov.au
+61 2 9463 1339
Heidi Tsang
Contact
heidi.tsang@health.nsw.gov.au
+61 2 9463 1340
George Hruby
principal investigator · Northern Sydney Local Health District

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion